4 Examples

IQnca contains a range of examples that are included in the examples/ folder of the installed R library. The folder can be conveniently copied to another directory by the function examples_IQnca. The default path to which the example material is copied is ~/IntiQuan/IQnca. Note that the working directory is also changed to this directory.

## IQnca documentation example material copied to: ~/IntiQuan/IQnca
## Working directory set to: ~/IntiQuan/IQnca
Table 4.1: Examples included in IQnca
Folder Subfolder Example
01_simple_linuplogdn 01_Indo_Lin_Bolus
02_Indo_Lin_Infusion
03_Ind_Lin_EV_wrong
05_Ind_Log_Bolus
06_Ind_Log_Infusion
07_Indo_Log_EV_wrong
08_Theoph_Linear
09_Theoph_Log
02_additional 01_LinUpLogDn 01_Extravascular
02_Extravascular_Repeat_Dose
03_Extravascular_Single_Dose
04_IV_Bolus_Single_Dose
05_IV_Inf_SD
02_Mixed 01_Extravascular_Single_Dose
02_EV_SD_Interp
03_Lin_LinInterp 04_IV_Bolus_Single_Dose
03_book_examples Example_1
Example_2
Example_3
Example_4
Example_5

The following examples showcase some of the features the IQnca package has to offer. For each individual example, the data contains a different combination of administration and profile type, and also the AUC calculation method varies.

  • Example 1 is an introductory analysis on bolus single dose data, demonstrating the visualization of the source data and the handling of outliers. Additional to the PK parameters calculation, the AUC on user selected intervals is calculated.
  • Example 2 handles LLOQ values and manual slope selection using infusion single dose data. A final report is generated showing listings, tables and figures.
  • Example 3 uses extravascular data containing both single dose and steady-state profiles. Through manual slope selection, the calculation of a slope is tried to be improved upon. A final report is generated showing listings, tables and figures.
  • Example 4 compares the output PK parameters of the IQnca calculations with those of WinNonlin, using the Theoph R data set.
  • Example 5 treats an edge case of the treatment of pre-dose entries.

4.1 Example 1: Bolus single dose data

This first example is a case study of an analysis with manual slope selection. The WinNonlin data set used is an IV bolus single dose data which can be found in examples/03_book_examples/Example_1/IV_Bolus_Single_Dose.xls. The data stems from a study X where the drug A was administered by IV to a group of 4 subjects. The drug was given as a 10,000 ug bolus dose. The given time unit is “Minutes”, the dosing unit is “ug” and the concentration was measured in “ng/mL”. More information about the dosing can be found in the supplied dosing data Dosing_Used.xls. In this example the AUC is determined by using the linear trapezoidal method on increasing parts of the curve and the logarithmic trapezoidal method on decreasing parts. Additionally, the AUCs of the time intervals [0H,6H] and [0H,12H] are calculated.

4.1.1 Data preparation

As a first step, import the source data set:

The first 15 rows of this data set are shown below.

Table 4.1: First 15 rows of the data set
Time Conc Subject Dose
min ug/L NA ug
10 920 1 10000
20 800 1 10000
30 750 1 10000
40 630 1 10000
50 610 1 10000
60 530 1 10000
70 520 1 10000
90 380 1 10000
110 350 1 10000
150 200 1 10000
10 850 2 10000
20 630 2 10000
30 580 2 10000
40 1020 2 10000

Most of the time a source data set, whether from WinNonlin or other sources, is not yet in the proper format to conduct an analysis. A preliminary step is to modify the original data set according to the IQnca specification. The names of existing relevant columns need to be mapped to column names given by the specification. Furthermore, required columns which are missing from the data set need to be added manually, provided such information exists. Table 3.1 (or calling dataSpec_IQdataNCA()) gives information on the necessary columns to build a minimally functioning example. Columns in the original data set which do not have a counterpart in the specification may simply be ignored.

In this example the columns ID, TIME, CONC, DOSE from the source data set were mapped to USUBJID, NTIME, ACONC, DOSE. The dosing information stems form the Dosing_Used.xls data.

Table 4.2: First five rows of the minimally required data set
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT LLOQ ADM DOSE DOSEUNIT
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 10 Minutes 920 ng/mL 0 Bolus 10000 ug
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 20 Minutes 800 ng/mL 0 Bolus 10000 ug
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 30 Minutes 750 ng/mL 0 Bolus 10000 ug
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 40 Minutes 630 ng/mL 0 Bolus 10000 ug
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 50 Minutes 610 ng/mL 0 Bolus 10000 ug

4.1.2 Apply analysis settings

The function IQdataNCA gives the user the ability to make individual choices about the AUC calculation method, the interpolation method and the handling of records with concentration values below the lower limit of quantification. In this example the AUC on increasing parts of the concentration curve is calculated by the linear trapezoidal method, and for decreasing parts the logarithmic trapezoidal rule is used (see section 6.6). Similarly, interpolation on increasing parts is done by linear rule and on decreasing parts by logarithmic rule. By setting the parameter FLAGTIME as “nominal” the TIME data from the original data set is taken as nominal time. Furthermore, by giving a character string of intervals in the parameter AUCINVAL, the AUC on those intervals may be returned. For more detailed information about the functionality of IQdataNCA refer to Chapter 5 Data Specification. An example of special handling of below LLOQ values is shown in Example 2.

Table 4.3: First five rows of the IQdataNCA object.
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT LLOQ ADM DOSE DOSEUNIT TAU ADUR NDUR VISIT VISITNUM PCTPT PCDTC EXSTDTC PERIOD SEQUENCE COUNTRY SITEID AGE SEX RACE IX COMPTYPE IGNOREI IGNORER IGNORSUM IGNORNCA COMMENTR COMMENTI ATAFD NTAFD FLAGTIME FATIMIMP TAFD TIME DUR BLLOQ BLLOQPR BLLOQIN BLLOQP1 BLLOQPO FLGBLQPR FLGBLQIN FLGBLQP1 FLGBLQPO FGBQPLIN FGBQPLOG CONC CONCPLIN CONCPLOG FLGSLOPE SLOPETOL SLOPEPT R2 R2ADJ LAMZNPT LAMZ LAMZICPT CORRXY LAMZLL LAMZUL CLSTP AUCMETHD AUCINVAL
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 10 MINUTES 920 ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1 exogenous NA NA NA NA NA NA NA 10 nominal asis 10 10 NA 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 920 920 920 bestslope 1e-04 1 0.9887083 0.9872969 10 0.0104409 6.918914 -0.9943381 10 150 211.1941 linearup logdown [0;6];[0;12]
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 20 MINUTES 800 ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2 exogenous NA NA NA NA NA NA NA 20 nominal asis 20 20 NA 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 800 800 800 bestslope 1e-04 1 0.9887083 0.9872969 10 0.0104409 6.918914 -0.9943381 10 150 211.1941 linearup logdown [0;6];[0;12]
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 30 MINUTES 750 ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 3 exogenous NA NA NA NA NA NA NA 30 nominal asis 30 30 NA 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 750 750 750 bestslope 1e-04 1 0.9887083 0.9872969 10 0.0104409 6.918914 -0.9943381 10 150 211.1941 linearup logdown [0;6];[0;12]
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 40 MINUTES 630 ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4 exogenous NA NA NA NA NA NA NA 40 nominal asis 40 40 NA 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 630 630 630 bestslope 1e-04 1 0.9887083 0.9872969 10 0.0104409 6.918914 -0.9943381 10 150 211.1941 linearup logdown [0;6];[0;12]
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug NA NA 50 MINUTES 610 ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5 exogenous NA NA NA NA NA NA NA 50 nominal asis 50 50 NA 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 610 610 610 bestslope 1e-04 1 0.9887083 0.9872969 10 0.0104409 6.918914 -0.9943381 10 150 211.1941 linearup logdown [0;6];[0;12]
##    Profile                | Number subjects | Number samples
##    ---------------------------------------------------------
##    Single Bolus Dose (SD) | 4               | 40

Plots allow to assess potential outliers and to select points that should be considered for slope calculation (if manual selection is desired). A first exploratory look into the data can be made by using the plot.IQdataNCA function. This plotting function is best used for data exploration; for reporting, different functions are used (see Example 2 Section 4.2.3). Individual plots show the individual profiles in different panels. The observation points are overlaid with labels, indicating the number of the sample (column IX in the IQdataNCA object). The user can choose between linear and log y axis.

Individual concentration curves of each subject, with y-axis log10 scaled

4.1.2.1 Data cleaning

By the visualization of the data it is revealed that Subject 2 possesses an implausible outlier. The plot enumerates each record by the column IX which simplifies the removal of the outlier. Remove the record from NCA consideration:

Concentration curve of Subject 2, outlier removed, with y-axis log10 scaled

4.1.2.2 Manual slope selection

The terminal slope for each subject is initially calculated by the best-slope algorithm. The slope parameters are automatically included in the IQdataNCA data set.

Table 4.4: Slope parameters of Subject 1, best-slope algorithm
FLGSLOPE SLOPETOL SLOPEPT R2 R2ADJ LAMZNPT LAMZ LAMZICPT CORRXY LAMZLL LAMZUL CLSTP
bestslope 1e-04 1 0.9887083 0.9872969 10 0.0104409 6.918914 -0.9943381 10 150 211.1941


For demonstration purposes, in this example for Subject 1 a different slope will be calculated and therefore the slope points for the first subject will be manually selected. The manual slope calculation is previewed with slopetest_IQnca.

## Determining slope based on provided points in IXslope

The slope parameters with the desired slope points are then recalculated in the IQdataNCA object by the slope_IQdataNCA function.

The new slope parameters for Subject 1:

Table 4.5: Slope parameters of Subject 1, manually selected slope
FLGSLOPE SLOPETOL SLOPEPT R2 R2ADJ LAMZNPT LAMZ LAMZICPT CORRXY LAMZLL LAMZUL CLSTP
manual 1e-04 0 0.982244 0.9763253 5 0.0110831 6.994555 -0.9910822 50 150 206.8693

4.1.3 NCA parameter calculation

dataNCA is an IQdataNCA object which can be used for the NCA parameter calculation. It is the input for the function nca_IQdataNCA which calculates the NCA parameters.

The output is an IQnca object which is a data frame containing all calculated PK parameters.

Table 4.6: The NCA parameters for each of the subjects
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU TIMEUNIT CONCUNIT LLOQ ADM DOSE DOSEUNIT TAU ADUR NDUR PERIOD SEQUENCE COUNTRY SITEID AGE SEX RACE COMPTYPE FLAGTIME FATIMIMP DUR FLGSLOPE SLOPETOL AUCMETHD AUCINVAL LAMZICPT CORRXY LAMZ LAMZNPT LAMZLL LAMZUL R2 R2ADJ LAMZHL SPAN TLAG C0 TMAX CMAX CMAXD TMIN CMIN CMIND TLST CLST CLSTP CAVG CTAU FLUCP FLUCPTAU AILAMZ SWING SWINGTAU AUCALL AUCIFO AUCIFOD AUCIFP AUCIFPD AUCLST AUCLSTD AUCPBEO AUCPBEP AUCPEO AUCPEP AUCTAU AUCTAUD CLFO CLFP CLFSS CLO CLP CLSS VSSO VSSP VZFO VZFP VZFSS VZO VZP VZSS AUMCIFO AUMCIFP AUMCLST AUMCPEO AUMCPEP AUMCTAU AUCPTAUE MRTEVIFO MRTEVIFP MRTEVLST MRTIVIFO MRTIVIFP MRTIVLST AUCINT1 AUCINT1D AUCINT2 AUCINT2D
1 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug MINUTES ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA exogenous nominal asis NA manual 1e-04 linearup logdown [0;6];[0;12] 6.994555 -0.9910822 0.0110831 5 50 150 0.9822440 0.9763253 62.54080 1.598956 NA 1058.0000 10 920 0.0920 150 200 0.0200 150 200 206.86930 NA NA NA NA NA NA NA 77174.24 95219.70 9.521970 95839.50 9.583950 77174.24 7.717424 10.369632 10.302571 18.951394 19.475539 NA NA NA NA NA 0.1050203 0.1043411 NA 9.582734 9.621291 NA NA NA 9.475697 9.414417 NA 8688465 8837358 4353453 49.89388 50.73807 NA NA NA NA NA 91.24651 92.20997 56.41070 6089.124 0.6089124 11688.454 1.1688454
2 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug MINUTES ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA exogenous nominal asis NA bestslope 1e-04 linearup logdown [0;6];[0;12] 6.952288 -0.9955550 0.0209562 9 10 150 0.9911298 0.9898626 33.07602 4.232674 NA 1146.8254 10 850 0.0850 150 42 0.0042 150 42 45.09903 NA NA NA NA NA NA NA 48500.64 50504.82 5.050482 50652.70 5.065270 48500.64 4.850064 19.622189 19.564901 3.968298 4.248664 NA NA NA NA NA 0.1980009 0.1974228 NA 9.361160 9.420541 NA NA NA 9.448328 9.420743 NA 2387785 2417024 1991521 16.59546 17.60441 NA NA NA NA NA 47.27837 47.71758 41.06176 6298.096 0.6298096 11560.235 1.1560235
3 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug MINUTES ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA exogenous nominal asis NA bestslope 1e-04 linearup logdown [0;6];[0;12] 6.877619 -0.9984467 0.0189195 10 10 150 0.9968957 0.9965077 36.63672 3.821303 NA 941.1765 10 800 0.0800 150 60 0.0060 150 60 56.80923 NA NA NA NA NA NA NA 48126.72 51298.06 5.129806 51129.41 5.112941 48126.72 4.812672 16.933918 16.989774 6.182177 5.872720 NA NA NA NA NA 0.1949392 0.1955822 NA 10.371467 10.309132 NA NA NA 10.303629 10.337616 NA 2729242 2695030 2085918 23.57151 22.60130 NA NA NA NA NA 53.20361 52.70998 43.34221 5380.468 0.5380468 10261.047 1.0261047
4 Study X Drug A Drug A Plasma Single Bolus Dose (SD) SD 10000 ug 10000 ug MINUTES ng/mL 0 BOLUS 10000 ug NA NA NA NA NA NA NA NA NA NA exogenous nominal asis NA bestslope 1e-04 linearup logdown [0;6];[0;12] 6.207537 -0.9971818 0.0096248 10 10 150 0.9943716 0.9936681 72.01703 1.943985 NA 540.5625 10 465 0.0465 150 120 0.0120 150 120 117.19292 NA NA NA NA NA NA NA 39568.22 52036.05 5.203605 51744.40 5.174440 39568.22 3.956822 9.643958 9.698315 23.959992 23.531400 NA NA NA NA NA 0.1921745 0.1932576 NA 20.028554 19.978403 NA NA NA 19.966660 20.079200 NA 5423233 5349183 2257667 58.37045 57.79416 NA NA NA NA NA 104.22069 103.37704 57.05760 3101.180 0.3101180 5934.471 0.5934471


Alternatively the IQnca object can displayed by calling the IQnca method print which is not shown here to avoid inflating the example.

4.2 Example 2: Infusion single dose data

The WinNonlin data set for the second example is an IV infusion single dose data which can be found in examples/03_book_examples/Example_2/IV_Infusion_Single_Dose.xls. The data stems from a study Y where the drug B was administered as a single infusion IV dose with a dosing of 300 mg/m2 to 3 subjects and 400mg/m2 to 2 subjects. More information about the dosing can be found in the supplied dosing data Dosing_Used.xls. The given time unit is “Hours”, the dosing unit is “mg” and the concentration was measured in “ug/mL”. In this example the AUC is determined by using the linear trapezoidal method on the curve before the time to Cmax (Tmax) and the logarithmic trapezoidal method for the part after Tmax. Possible interpolation is done by using the linear or logarithmic rule, on the respective parts of the curve. An alternative BLQ value handling will be applied. A report of the data and results is then generated using the following figures, listings and tables:

  • Figures
    • Multiple stratified spaghetti concentration plots,
    • Individual plots of the concentration data,
    • Mean plot of the concentration,
    • Geomean plots of the concentration.
  • Listings
    • Concentration listing,
    • Time sampling listing,
    • PK parameter listing.
  • Tables
    • Concentration summary table,
    • PK parameter summary table.

4.2.1 Data preparation

The first 15 rows of this data set are shown below.

Table 4.1: First 15 rows of the data set
ID Dose Dose_1 Timepoint Actual_time Nominal_time Conc BSA Sex Age
NA mg_m2 mg NA h h ug/mL m2 NA NA
1 300 540 0 HR -1.8300000000000001 0 BLQ 1.8 Female 35
1 300 540 0.5 HR 0.57999999999999996 0.5 17.7 1.8 Female 35
1 300 540 Infusion End 1.9199999999999999 2 75.4 1.8 Female 35
1 300 540 8 HR 7.7999999999999998 8 64 1.8 Female 35
1 300 540 Day 1 25.25 24 55.2 1.8 Female 35
1 300 540 Day 2 49.079999999999998 48 49.1 1.8 Female 35
1 300 540 Day 3 76.280000000000001 72 42.3 1.8 Female 35
1 300 540 Wk 1 193.33000000000001 168 27.5 1.8 Female 35
1 300 540 Day 10 244.41999999999999 240 27.4 1.8 Female 35
1 300 540 Wk 2 358.10000000000002 336 21.3 1.8 Female 35
1 300 540 Wk 4 699.04999999999995 672 10.3 1.8 Female 35
1 300 540 0 HR 1055.4200000000001 1008 7.1 1.8 Female 35
2 300 660 0 HR -2.1200000000000001 0 BLQ 2.2000000000000002 Male 41
2 300 660 0.5 HR 0.55000000000000004 0.5 33.3 2.2000000000000002 Male 41

Note the fact that the rows with concentrations below the LLOQ hold the non-numeric entry “BLQ” in the “Conc” column. This is a characteristic of WinNonlin data sets which needs to be modified before using the IQdataNCA function since the concentration columns (ACONC) may only be numeric. In cases like this it is important to replace the strings by values smaller than the LLOQ (here the LLOQ is 5).

Augment the original data set according to the IQnca specification:

Table 4.7: First five rows of the augmented data set
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT LLOQ ADM DOSE DOSEUNIT NDUR ADUR SEX AGE
1 Study Y Drug B Drug B Plasma Single IV Infusion Dose (SD) SD 300mg/m2 300 mg/m2 NA -1.83 0.0 Hours 0.0 ug/mL 5 Infusion 540 mg 2 1.83 Female 35
1 Study Y Drug B Drug B Plasma Single IV Infusion Dose (SD) SD 300mg/m2 300 mg/m2 NA 0.58 0.5 Hours 17.7 ug/mL 5 Infusion 540 mg 2 1.83 Female 35
1 Study Y Drug B Drug B Plasma Single IV Infusion Dose (SD) SD 300mg/m2 300 mg/m2 NA 1.92 2.0 Hours 75.4 ug/mL 5 Infusion 540 mg 2 1.83 Female 35
1 Study Y Drug B Drug B Plasma Single IV Infusion Dose (SD) SD 300mg/m2 300 mg/m2 NA 7.80 8.0 Hours 64.0 ug/mL 5 Infusion 540 mg 2 1.83 Female 35
1 Study Y Drug B Drug B Plasma Single IV Infusion Dose (SD) SD 300mg/m2 300 mg/m2 NA 25.25 24.0 Hours 55.2 ug/mL 5 Infusion 540 mg 2 1.83 Female 35

4.2.2 BLQ data handling

The IQdataNCA function provides multiple options for handling LLOQ data. In this example, BLQ values before the first time above the LLOQ are set to LLOQ/2, BLQ values in the middle are left as is, and trailing BLQ values are set to zero. Of note, the LLOQ in this example is 5 ug/mL.

Individual concentration curves of each subject

4.2.3 Data listings and tables

The data is reported in comprehensive listings, the concentration statistics are consolidated in a summary table. A concentration listing, a time listing and a concentration summary table will be generated. For a complete list of table and listing functions, refer to Table 3.4.

Generate the listings of the concentrations.

## Generating PK concentration listings ...

Shown below is only the first profile group:

#* Listing 2.1 Individual concentration data
!BLOCKSTART[keepNext](indiv2_1)
**Listing 2.1-1 Individual concentration data of Plasma Drug B (Drug B) - Single IV Infusion Dose (SD) (1 of 2)**
!TABINLINE[size:8,ignoreCaption:true,valueTable:false]
|               |             | Nominal Time [h]          |      |       |      |      |      |      |      |      |      |
| ------------- | ----------- | ------------------------- | ---- | ----- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
|               |             | 0                         | 0.5  | 2     | 8    | 24   | 48   | 72   | 168  | 240  | 336  |
| **Treatment** | **Subject** | **Concentration [ug/mL]** |      |       |      |      |      |      |      |      |      |
| 300mg/m2      | 1           | BLQ                       | 17.7 | 75.4  | 64   | 55.2 | 49.1 | 42.3 | 27.5 | 27.4 | 21.3 |
|               | 2           | BLQ                       | 33.3 | 157.2 | 97.7 | 94.3 | 91.7 | 80   | 62.1 | 52.8 | 42.8 |
|               | 3           | BLQ                       | 26.2 | 92.3  | 94.9 | 79.1 | 63.7 | 62.6 | 57.3 | 38.6 | 37.4 |
{NS: No Sample.<br>BLQ: Below lower limit of quantitation.<br>Lower limit of quantitation is 5 ug/mL.<br>IQnca version: 1.0.1.9000<br>Script: compliance<br>Output: output/listings/listing_concentrations.rmd<br>Execution date: 2021-09-22 12:55:18}

!BLOCKEND(indiv2_1)

!NEWPAGE

!BLOCKSTART[keepNext](indiv2_1)
**Listing 2.1-1 Individual concentration data of Plasma Drug B (Drug B) - Single IV Infusion Dose (SD) (2 of 2)**
!TABINLINE[size:8,ignoreCaption:true,valueTable:false]
|               |             | Nominal Time [h]          |      |
| ------------- | ----------- | ------------------------- | ---- |
|               |             | 672                       | 1008 |
| **Treatment** | **Subject** | **Concentration [ug/mL]** |      |
| 300mg/m2      | 1           | 10.3                      | 7.1  |
|               | 2           | 24.5                      | 12.7 |
|               | 3           | 20.1                      | 8.6  |
{NS: No Sample.<br>BLQ: Below lower limit of quantitation.<br>Lower limit of quantitation is 5 ug/mL.<br>IQnca version: 1.0.1.9000<br>Script: compliance<br>Output: output/listings/listing_concentrations.rmd<br>Execution date: 2021-09-22 12:55:18}

View the full concentration listing

The listings of the time data:

## Generating PK sampling time listings ...

View the full time data listing

Generate also the table of the concentration summary statistics.

## Generating PK concentration summary tables ...
|               |              | Nominal Time [h]          |       |       |       |       |       |       |       |       |       |
| ------------- | ------------ | ------------------------- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
|               |              | 0                         | 0.5   | 2     | 8     | 24    | 48    | 72    | 168   | 240   | 336   |
| **Treatment** | **Stats**    | **Concentration [ug/mL]** |       |       |       |       |       |       |       |       |       |
| 300mg/m2      | N            | 3                         | 3     | 3     | 3     | 3     | 3     | 3     | 3     | 3     | 3     |
|               | Mean         | 2.5                       | 25.73 | 108.3 | 85.53 | 76.2  | 68.17 | 61.63 | 48.97 | 39.6  | 33.83 |
|               | SD           | 0                         | 7.81  | 43.18 | 18.7  | 19.71 | 21.65 | 18.87 | 18.74 | 12.73 | 11.18 |
|               | Min          | 2.5                       | 17.7  | 75.4  | 64    | 55.2  | 49.1  | 42.3  | 27.5  | 27.4  | 21.3  |
|               | Median       | 2.5                       | 26.2  | 92.3  | 94.9  | 79.1  | 63.7  | 62.6  | 57.3  | 38.6  | 37.4  |
|               | Geo-mean     | 2.5                       | 24.9  | 103   | 84.03 | 74.39 | 65.95 | 59.61 | 46.08 | 38.22 | 32.43 |
|               | Max          | 2.5                       | 33.3  | 157.2 | 97.7  | 94.3  | 91.7  | 80    | 62.1  | 52.8  | 42.8  |
|               | CV% mean     | 0                         | 30.35 | 39.87 | 21.86 | 25.87 | 31.76 | 30.61 | 38.28 | 32.15 | 33.06 |
|               | CV% geo-mean | 0                         | 32.73 | 39.36 | 23.96 | 27.81 | 32.17 | 32.99 | 47.25 | 33.71 | 38.32 |
{NC: Not calculated.<br>Geo-mean: Geometric mean.<br>CV%% mean = coefficient of variation (%%)=SD/mean * 100.<br>CV%% geo-mean=(sqrt (exp (variance for log transformed data)-1)) * 100.<br>Lower limit of quantitation: 5 ug/mL. Pre-first dose <LLOQ values were handled as: LLOQ/2. <LLOQ values between >=LLOQ values were handled as: asis. First <LLOQ value post last >= LLOQ was handled as: 0. Second to last First <LLOQ value post last >= LLOQ was handled as: 0.<br>Values in table are reported with 4 significant digits.<br>IQnca version: 1.0.1.9000<br>Script: compliance<br>Output: output/tables/summary_table_conc.rmd<br>Execution date: 2021-09-22 12:55:18}

View the full table

4.2.4 Data plots

For the final report, figures of the data and summary statistics are generated. While the plot.IQdataNCA function is useful for data exploration, for reporting more sophisticated plotting functions are being used. The figures are exported into PDF files and also into .Rmd code is generated which is used for the final report. For a complete list of plotting functions, see Table 3.4.

4.2.4.1 Summary level plots

Summary level plots show the data in the same plots. Both on linear and log Y axis and both untransformed and dose-normalized. For each GROUP and PROFILE, a separate plot is created. In this example there are two dosing groups and a single profile. Stratification by various columns of the data is expressed by the coloring of the curves. In the following example the spaghetti plot is stratified by USUBJID.


The horizontal dashed line in the figure above marks the LLOQ. Below an example with stratification by SEX, linear scale y-axis and dose-normalized concentration.

Spaghetti plot of the concentration data, stratified by SEX, dose-normalized

The stratified columns can contain categorical or continuous data, but the latter is only recommended if there is a small finite number of unique values in the column. An example of a spaghetti plot, stratified by the continuous column AGE:

Spaghetti plot of the concentration data, stratified by AGE, dose-normalized

4.2.4.2 Individual plots

Individual plots show the individual profiles in different panels. Plots are produced both on a linear and log Y axis.

Individual concentration curves of each subject, with y-axis log10 scaled

4.2.4.3 Mean plots

Mean plots show binned mean and geometric mean plots with and without standard errors on linear and log Y axis. For each group, defined by a different entry in the GROUP column, a line is plotted. Below, both mean and geometric mean plots are shown.

Mean plot of the concentration data, with upper standard deviation

Geometric mean plot of the concentration data, with upper geometric standard deviation

Geometric mean plot of the concentration data, with log10 scaled y-axis, with upper geometric standard deviation

4.2.6 Result listings and tables

Export the resulting PK parameters as listings and tables. For a complete overview over the possible PK listing and table functions, see Table 3.5.

## Generating PK parameter listings ...

The PK parameter listing of the first subject:

**Listing 2.3-1 Individual pharmacokinetic parameters of Plasma Drug B (Drug B)**

* USUBJID: 1
* Age: 35
* Gender: Female

!TABINLINE[size:8,ignoreCaption:true,valueTable:false]
| Profile                      | Group    | Dose [mg] | Description                           | Parameter (Unit)    | Value      |
| ---------------------------- | -------- | --------- | ------------------------------------- | ------------------- | ---------- |
| Single IV Infusion Dose (SD) | 300mg/m2 | 540       | Number of Points for Lambda z         | LAMZNPT (-)         | 5          |
|                              |          |           | R Squared Adjusted                    | R2ADJ (-)           | 0.970477   |
|                              |          |           | Half-Life Lambda z                    | LAMZHL (h)          | 398.976    |
|                              |          |           | Span                                  | SPAN (-)            | 2.10539    |
|                              |          |           | Time of CMAX                          | TMAX (h)            | 2          |
|                              |          |           | Max Conc                              | CMAX (mg/L)         | 75.4       |
|                              |          |           | Max Conc Norm by Dose                 | CMAXD (mg/L/mg)     | 0.13963    |
|                              |          |           | Time of CMIN Observation              | TMIN (h)            | 0          |
|                              |          |           | Min Conc                              | CMIN (mg/L)         | 2.5        |
|                              |          |           | Min Conc Norm by Dose                 | CMIND (mg/L/mg)     | 0.00462963 |
|                              |          |           | Time of Last Nonzero Conc             | TLST (h)            | 1008       |
|                              |          |           | Last Nonzero Conc                     | CLST (mg/L)         | 7.1        |
|                              |          |           | Last Nonzero Conc Pred                | CLSTP (mg/L)        | 6.59407    |
|                              |          |           | AUC All                               | AUCALL (mg/L*h)     | 19367.2    |
|                              |          |           | AUC Infinity Obs                      | AUCIFO (mg/L*h)     | 23453.9    |
|                              |          |           | AUC Infinity Obs Norm by Dose         | AUCIFOD (mg/L*h/mg) | 43.4332    |
|                              |          |           | AUC Infinity Pred                     | AUCIFP (mg/L*h)     | 23162.7    |
|                              |          |           | AUC Infinity Pred Norm by Dose        | AUCIFPD (mg/L*h/mg) | 42.8939    |
|                              |          |           | AUC to Last Nonzero Conc              | AUCLST (mg/L*h)     | 19367.2    |
|                              |          |           | AUC to Last Nonzero Conc Norm by Dose | AUCLSTD (mg/L*h/mg) | 35.8651    |
|                              |          |           | AUC %Extrapolation Obs                | AUCPEO (%)          | 17.4247    |
|                              |          |           | AUC %Extrapolation Pred               | AUCPEP (%)          | 16.3865    |
|                              |          |           | Total CL Obs                          | CLO (L/h)           | 0.0230239  |
|                              |          |           | Total CL Pred                         | CLP (L/h)           | 0.0233133  |
|                              |          |           | Vol Dist Steady State Obs             | VSSO (L)            | 12.6509    |
|                              |          |           | Vol Dist Steady State Pred            | VSSP (L)            | 12.5071    |
|                              |          |           | Vz Obs                                | VZO (L)             | 13.2526    |
|                              |          |           | Vz Pred                               | VZP (L)             | 13.4192    |
{NC: Not calculated.<br>Number of significant digits: 6<br>IQnca version: 1.0.1.9000<br>Script: compliance<br>Output: output/listings/listing_pkparameter.rmd<br>Execution date: 2021-09-22 12:55:21}

View the full PK parameters listing

## Generating PK parameter summary tables ...

View the full table

4.2.7 Reporting

In the final report, the previously exported figures, listings and tables are consolidated in a single Word document. The list of export functions used for the creation of figures, lists and tables in this example is by no means exhaustive.

View the final report

4.3 Example 3: Extravascular first dose and steady state

The PK of the drug candidate C under repeated dosing was investigated in a single-arm study Z. A 10 mg dose of C was given once daily for one week to 10 healthy individuals. PK profiles in plasma were monitored on Day 1 and after the last dose on Day 7. For Day 1, the profile was obtained for the dosing interval whereas the Day 7 profile monitored the washout up to one week after the last dose.

To investigate and compare the PK characteristics after first dose and at the assumed steady-state, an NCA is conducted for both profiles. The AUC is to be calculated based on linear trapezoidal rule before the maximum concentration and based on logarithmic trapezoidal rule afterwards. The standard settings for BLQ handling are applied.

4.3.1 Data exploration

The PK data is provided in the IQncaData input format, i.e., all required columns for importing the data as IQRdataNCA are prepared.

Table 4.8: First five rows of the minimally required data set
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT LLOQ ADM DOSE DOSEUNIT TAU
1 Z C C Plasma First dose FD 10mg_OD_Oral 10 mg 1 0.0000 0.0000 Hours 0.3689 ng/mL 1 EXTRAVASCULAR 10 mg 24
1 Z C C Plasma First dose FD 10mg_OD_Oral 10 mg 1 0.1667 0.1667 Hours 24.2235 ng/mL 1 EXTRAVASCULAR 10 mg 24
1 Z C C Plasma First dose FD 10mg_OD_Oral 10 mg 1 1.0000 1.0000 Hours 74.1386 ng/mL 1 EXTRAVASCULAR 10 mg 24
1 Z C C Plasma First dose FD 10mg_OD_Oral 10 mg 1 2.0000 2.0000 Hours 134.2214 ng/mL 1 EXTRAVASCULAR 10 mg 24
1 Z C C Plasma First dose FD 10mg_OD_Oral 10 mg 1 4.0000 4.0000 Hours 131.8492 ng/mL 1 EXTRAVASCULAR 10 mg 24


Such, the input dataset can readily be imported by IQdataNCA for analysis preparation, i.e., defining the analysis setting in the data set. The summary function provides an overview over the number of subjects and observations for each profile. Here, the numbers reported are as expected.

   Profile           | Number subjects | Number samples
   ----------------------------------------------------
   First dose        | 10              | 90            
   Steady-state dose | 10              | 120           

The exploratory plots show the individual profiles. No obvious outlier is visible, but for subject 1 the slope for the steady-state profile with washout could not be determined precisely.

Exploratory data plots

## Determining slope based on provided points in IXslope
## Determining slope based on provided points in IXslope
## Determining slope based on provided points in IXslope
## Determining slope based on provided points in IXslope

Checking slope for steady-state profile of subject 1

As the exploratory data analysis indicates that there are no outliers to be removed and the slope calculation cannot be improved via manual tuning, the NCA is conducted without further modifications of the dataset or settings.

4.4 Example 4: Single oral dose data

This example calculates the NCA parameters of the Theoph dataset and compares the parameters calculated in WinNonlin with the results of IQnca. The WinNonlin calculated data can be found in FPP_Theoph_Log.csv. The data stems from the Theoph R data set where the drug theophylline was administered orally to a group of 12 subjects. The drug was given as a 320 mg single dose. The given time unit is “Hours”, the dosing unit is “mg” and the concentration was measured in “ug/mL”.

4.4.1 NCA parameter calculation

Import the data, augment it via IQdataNCA and calculate the NCA parameters.


The actual time column is used to calculate the parameters. For comparisons with other NCA tools it is recommended to set the option FLAGignore to FALSE.

4.4.2 Comparison of results

Compare the NCA parameter calculations of WinNonlin and IQnca on the Theoph data. The WinNonlin results are found in FPP_Theoph_Log.csv.

Table 4.9: Winnonlin NCA parameters
Subject Rsq Rsq_adjusted Corr_XY No_points_lambda_z Lambda_z Lambda_z_lower Lambda_z_upper HL_Lambda_z Tlag Tmax Cmax Cmax_D Tlast Clast AUClast AUCall AUCINF_obs AUCINF_D_obs AUC_%Extrap_obs Vz_F_obs Cl_F_obs AUCINF_pred AUCINF_D_pred AUC_%Extrap_pred Vz_F_pred Cl_F_pred AUMClast AUMCINF_obs AUMC_%Extrap_obs AUMCINF_pred AUMC_%Extrap_pred MRTlast MRTINF_obs MRTINF_pred
1 0.9999997 0.9999995 -0.9999999 3 0.0484570 9.05 24.37 14.304378 0 1.12 10.50 0.0328125 24.37 3.28 147.23475 147.23475 214.92363 0.6716363 31.494388 30.72623 1.488901 214.92665 0.6716458 31.495352 30.72580 1.488880 1499.1291 4545.593 67.02016 4545.729 67.02115 10.181897 21.14980 21.15014
2 0.9971954 0.9957931 -0.9985967 4 0.1040864 7.03 24.30 6.659342 0 1.92 8.33 0.0260312 24.30 0.90 88.73128 88.73128 97.37793 0.3043060 8.879485 31.57150 3.286165 97.26879 0.3039650 8.777242 31.60693 3.289853 716.2787 1009.464 29.04369 1005.764 28.78261 8.072449 10.36646 10.34005
3 0.9993250 0.9986499 -0.9996624 3 0.1024443 9.00 24.17 6.766087 0 1.02 8.20 0.0256250 24.17 1.05 95.87820 95.87820 106.12767 0.3316490 9.657680 29.43293 3.015236 106.17742 0.3318044 9.700011 29.41914 3.013823 810.8727 1158.652 30.01583 1160.340 30.11765 8.457321 10.91753 10.92831

As comparison, the first three rows of the previously calculated NCA parameters.
Table 4.3: IQnca NCA parameters
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU TIMEUNIT CONCUNIT LLOQ ADM DOSE DOSEUNIT TAU ADUR NDUR PERIOD SEQUENCE COUNTRY SITEID AGE SEX RACE COMPTYPE FLAGTIME FATIMIMP DUR FLGSLOPE SLOPETOL AUCMETHD WT0 AUCINVAL LAMZICPT CORRXY LAMZ LAMZNPT LAMZLL LAMZUL R2 R2ADJ LAMZHL SPAN TLAG C0 TMAX CMAX CMAXD TMIN CMIN CMIND TLST CLST CLSTP CAVG CTAU FLUCP FLUCPTAU AILAMZ SWING SWINGTAU AUCALL AUCIFO AUCIFOD AUCIFP AUCIFPD AUCLST AUCLSTD AUCPBEO AUCPBEP AUCPEO AUCPEP AUCTAU AUCTAUD CLFO CLFP CLFSS CLO CLP CLSS VSSO VSSP VZFO VZFP VZFSS VZO VZP VZSS AUMCIFO AUMCIFP AUMCLST AUMCPEO AUMCPEP AUMCTAU AUCPTAUE MRTEVIFO MRTEVIFP MRTEVLST MRTIVIFO MRTIVIFP MRTIVLST
1 Theop R dataset Theop Theop Plasma SD profile SD 320 mg SD 320 mg HOURS ug/mL 0 EXTRAVASCULAR 320 mg 24 NA NA NA NA NA NA NA NA NA exogenous actual asis NA bestslope 1e-04 linearup logdown 79.6 NA 2.368785 -0.9999999 0.0484570 3 9.05 24.37 0.9999997 0.9999995 14.304378 1.071001 0 0.74 1.12 10.50 0.0328125 0 0.74 0.0023125 24.37 3.28 3.2801465 NA NA NA NA NA NA NA 147.23475 214.92363 0.6716363 214.92665 0.6716458 147.23475 0.4601086 NA NA 31.494388 31.495352 NA NA 1.488901 1.488880 NA NA NA NA NA NA 30.72623 30.72580 NA NA NA NA 4545.593 4545.729 1499.1291 67.02016 67.02115 NA NA 21.14980 21.15014 10.181897 NA NA NA
2 Theop R dataset Theop Theop Plasma SD profile SD 320 mg SD 320 mg HOURS ug/mL 0 EXTRAVASCULAR 320 mg 24 NA NA NA NA NA NA NA NA NA exogenous actual asis NA bestslope 1e-04 linearup logdown 72.4 NA 2.411237 -0.9985967 0.1040864 4 7.03 24.30 0.9971954 0.9957931 6.659342 2.593349 0 0.00 1.92 8.33 0.0260312 0 0.00 0.0000000 24.30 0.90 0.8886398 NA NA NA NA NA NA NA 88.73128 97.37793 0.3043060 97.26879 0.3039650 88.73128 0.2772852 NA NA 8.879485 8.777242 NA NA 3.286165 3.289853 NA NA NA NA NA NA 31.57150 31.60693 NA NA NA NA 1009.464 1005.764 716.2787 29.04369 28.78261 NA NA 10.36646 10.34005 8.072449 NA NA NA
3 Theop R dataset Theop Theop Plasma SD profile SD 320 mg SD 320 mg HOURS ug/mL 0 EXTRAVASCULAR 320 mg 24 NA NA NA NA NA NA NA NA NA exogenous actual asis NA bestslope 1e-04 linearup logdown 70.5 NA 2.529711 -0.9996624 0.1024443 3 9.00 24.17 0.9993250 0.9986499 6.766087 2.242064 0 0.00 1.02 8.20 0.0256250 0 0.00 0.0000000 24.17 1.05 1.0550967 NA NA NA NA NA NA NA 95.87820 106.12767 0.3316490 106.17742 0.3318044 95.87820 0.2996194 NA NA 9.657680 9.700011 NA NA 3.015236 3.013823 NA NA NA NA NA NA 29.43293 29.41914 NA NA NA NA 1158.652 1160.340 810.8727 30.01583 30.11765 NA NA 10.91753 10.92831 8.457321 NA NA NA


The comparison function maps the WinNonlin parameter names to IQnca and compares each parameter by taking the relative error (absolute error if the WinNonlin parameter is zero). The tolerance is set to 1e-6.

## [1] "Issues in 0 cases."

4.5 Example 5: Special pre-dose handling

In data sets where the drug is administered over multiple profile days, it may be desired to add the pre-dose of a given day as last entry of the previous day, i.e. treating the pre-dose value as part of the concentration curve of the previous day. This may be accomplished by duplicating the pre-dose rows and appending them to the previous day. Note that then the duplicated values are used twice for AUC calculation, once as last record of the previous day and once as pre-dose value. Also the duplicated records are listed twice for listings and table.

Table 4.10: Excerpt of the input data with the most important columns
USUBJID PROFILE PROFTYPE DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT PCTPT
1 Day 1 FD 1 -0.0800 0.0000 Hours 0.2894 ng/mL PREDOSE
1 Day 1 FD 1 0.1667 0.1667 Hours 353.6291 ng/mL 10MIN
1 Day 1 FD 1 1.0000 1.0000 Hours 296.2243 ng/mL 1H
1 Day 1 FD 1 2.0000 2.0000 Hours 281.7309 ng/mL 2H
1 Day 1 FD 1 4.0000 4.0000 Hours 274.1404 ng/mL 4H
1 Day 1 FD 1 12.0000 12.0000 Hours 129.2435 ng/mL 12H
1 Day 2 SS 2 -0.0800 0.0000 Hours 193.4719 ng/mL PREDOSE
1 Day 2 SS 2 0.1667 0.1667 Hours 501.4376 ng/mL 10MIN
1 Day 2 SS 2 1.0000 1.0000 Hours 414.5653 ng/mL 1H
1 Day 2 SS 2 2.0000 2.0000 Hours 427.8838 ng/mL 2H
1 Day 2 SS 2 4.0000 4.0000 Hours 456.6272 ng/mL 4H
1 Day 2 SS 2 12.0000 12.0000 Hours 224.3079 ng/mL 12H

4.5.1 Duplicating the pre-dose records

Table 4.1: Excerpt of the data set with the most important columns
USUBJID PROFILE PROFTYPE DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT PCTPT
1 Day 1 FD 1 4.0000 4.0000 Hours 274.1404 ng/mL 4H
1 Day 1 FD 1 12.0000 12.0000 Hours 129.2435 ng/mL 12H
1 Day 1 FD 1 NA 24.0000 Hours 193.4719 ng/mL 24H
1 Day 2 SS 2 -0.0800 0.0000 Hours 193.4719 ng/mL PREDOSE
1 Day 2 SS 2 0.1667 0.1667 Hours 501.4376 ng/mL 10MIN
Table 4.2: Excerpt of the dataNCA
USUBJID STUDYID COMPOUND ANALYTE MATRIX PROFILE PROFTYPE GROUP GROUPN GROUPU DAY ATIME NTIME TIMEUNIT ACONC CONCUNIT LLOQ ADM DOSE DOSEUNIT TAU ADUR NDUR VISIT VISITNUM PCTPT PCDTC EXSTDTC PERIOD SEQUENCE COUNTRY SITEID AGE SEX RACE IX COMPTYPE IGNOREI IGNORER IGNORSUM IGNORNCA COMMENTR COMMENTI ATAFD NTAFD FLAGTIME FATIMIMP TAFD TIME DUR BLLOQ BLLOQPR BLLOQIN BLLOQP1 BLLOQPO FLGBLQPR FLGBLQIN FLGBLQP1 FLGBLQPO FGBQPLIN FGBQPLOG CONC CONCPLIN CONCPLOG FLGSLOPE SLOPETOL SLOPEPT R2 R2ADJ LAMZNPT LAMZ LAMZICPT CORRXY LAMZLL LAMZUL CLSTP AUCMETHD AUCINVAL
1 AAA ZZZ ZZZ Plasma Day 1 FD 10mg_BID_BBB 10 mg 1 4.0000 4.0000 HOURS 274.1404 ng/mL 1 INFUSION 10 mg 12 0.1666667 0.1666667 NA NA 4H NA NA NA NA NA NA NA NA NA 5 exogenous NA NA NA NA NA NA 4.0000 4.0000 nominal asis 4.0000 4.0000 0.1666667 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 274.1404 274.1404 274.1404 bestslope 1e-04 1 0.4917295 0.3646619 6 0.0276014 5.688708 -0.7012343 0.1667 24 152.3644 linear log NA
1 AAA ZZZ ZZZ Plasma Day 1 FD 10mg_BID_BBB 10 mg 1 12.0000 12.0000 HOURS 129.2435 ng/mL 1 INFUSION 10 mg 12 0.1666667 0.1666667 NA NA 12H NA NA NA NA NA NA NA NA NA 6 exogenous NA NA NA NA NA NA 12.0000 12.0000 nominal asis 12.0000 12.0000 0.1666667 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 129.2435 129.2435 129.2435 bestslope 1e-04 1 0.4917295 0.3646619 6 0.0276014 5.688708 -0.7012343 0.1667 24 152.3644 linear log NA
1 AAA ZZZ ZZZ Plasma Day 1 FD 10mg_BID_BBB 10 mg 1 NA 24.0000 HOURS 193.4719 ng/mL 1 INFUSION 10 mg 12 0.1666667 0.1666667 NA NA 24H NA NA NA NA NA NA NA NA NA 7 exogenous NA NA NA NA NA NA NA 24.0000 nominal asis 24.0000 24.0000 0.1666667 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 193.4719 193.4719 193.4719 bestslope 1e-04 1 0.4917295 0.3646619 6 0.0276014 5.688708 -0.7012343 0.1667 24 152.3644 linear log NA
1 AAA ZZZ ZZZ Plasma Day 2 SS 10mg_BID_BBB 10 mg 2 -0.0800 0.0000 HOURS 193.4719 ng/mL 1 INFUSION 10 mg 12 0.1666667 0.1666667 NA NA PREDOSE NA NA NA NA NA NA NA NA NA 1 exogenous NA NA NA NA NA NA -0.0800 0.0000 nominal asis 0.0000 0.0000 0.1666667 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 193.4719 193.4719 193.4719 bestslope 1e-04 0 0.9273353 0.8546706 3 0.0715183 6.294356 -0.9629825 2.0000 12 229.5536 linear log NA
1 AAA ZZZ ZZZ Plasma Day 2 SS 10mg_BID_BBB 10 mg 2 0.1667 0.1667 HOURS 501.4376 ng/mL 1 INFUSION 10 mg 12 0.1666667 0.1666667 NA NA 10MIN NA NA NA NA NA NA NA NA NA 2 exogenous NA NA NA NA NA NA 0.1667 0.1667 nominal asis 0.1667 0.1667 0.1666667 0 0 0 0 0 0 missing lloq/2 missing asconc asconc 501.4376 501.4376 501.4376 bestslope 1e-04 0 0.9273353 0.8546706 3 0.0715183 6.294356 -0.9629825 2.0000 12 229.5536 linear log NA

This method is useful in data sets with multiple dosing days where AUC calculation of all data right up to subsequent drug administration is desired. Note that the duplicated data is also duplicated in the summary tables, figures and listings.